Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures.

Haemonetics Corporation (HAE), a blood management solutions provider, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a B VGM Score. The stock has gained 14.8% over the past four weeks, driven by positive momentum. Two analysts revised earnings estimates upward in the last 60 days, with the Zacks Consensus Estimate increasing to $5.29 per share for fiscal 2027, and the company maintains a +6% average earnings surprise.

Haemonetics shares surged 17.5% following CSL's announcement of a supply agreement rollout across U.S. plasma collection centers by end of 2027. The company expects Q earnings of $1.30 per share (+2.4% YoY) with revenues of $346.84 million (+6% YoY). However, analysts caution that without earnings estimate revisions, the stock may struggle to sustain momentum. HAE carries a Zacks Rank #3 (Hold).

In a comparison of two Medical-Products sector stocks, Phibro Animal Health (PAHC) emerges as the better value opportunity compared to Haemonetics (HAE). PAHC holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a forward P/E of 10.06 and PEG ratio of 1.02. HAE has a Zacks Rank #3 (Hold) with a Value grade of C, showing a forward P/E of 20.36 and PEG ratio of 2.15, making PAHC more attractive to value investors.

In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive value investment option compared to Haemonetics (HAE). GEHC holds a Zacks Rank #2 (Buy) with a Value grade of B, featuring a lower forward P/E ratio of 14.54 and P/B ratio of 2.95. HAE, ranked #3 (Hold) with a Value grade of C, has a higher forward P/E of 19.67 and P/B of 5.64, suggesting GEHC offers better value metrics and a more improving earnings outlook.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.

The global therapeutic apheresis market is projected to grow from USD 3.84 billion in 2025 to USD 8.94 billion by 2035, at a CAGR of 7.9%. Growth is driven by increased prevalence of chronic and autoimmune diseases, technological advancements in automated systems, and improved reimbursement policies. Key players include Terumo BCT, Fresenius Kabi, Haemonetics, and B. Braun Melsungen.

Haemonetics Corporation announced the acquisition of Ireland-based Vivasure Medical Limited for €100 million upfront plus up to €85 million in milestone-based payments. The deal adds Vivasure's PerQseal Elite system, a bioabsorbable patch for large-bore vascular access closure, to Haemonetics' interventional portfolio. The technology has received CE Mark approval in Europe and submitted FDA Premarket Approval in the U.S., with strong clinical data showing no major complications.

The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.

Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.

The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.

The global apheresis equipment market is expected to grow from $4.17 billion in 2023 to $13.17 billion by 2033, at a CAGR of 12.2%. Key drivers include the increasing prevalence of chronic diseases, technological advancements, and growing demand for blood components.